TLDR Cells from a skin condition can create new hair follicles and similar growths in mice, and a specific treatment can reduce these effects.
The study from 2011 explored the potential of TSC2-null fibroblast-like cells, derived from human tuberous sclerosis complex (TSC) skin hamartomas, to induce hair follicle formation and hamartoma morphogenesis when grafted onto immunodeficient mice. These cells, combined with normal human keratinocytes, led to the development of complete hair follicles and exhibited characteristics of TSC skin hamartomas, such as increased mTORC1 activity, angiogenesis, and epidermal proliferation. Treatment with the mTORC1 inhibitor rapamycin normalized these features and reduced tumor cell numbers, suggesting therapeutic potential. The study involved grafting experiments on a total of 54 mice, divided into groups with normal fibroblasts and TSC2-null cells, both with and without rapamycin treatment. The findings highlight the role of TSC2-null cells in tissue morphogenesis and the possibility of manipulating the TSC1/TSC2/mTORC1 pathway for follicle induction and tumor treatment.View this study on nature.com →
CK15 is not a reliable marker for stem cells in damaged hair follicles from patients with CCCA.
Dermal cells are key in controlling hair growth and could potentially be used in hair loss treatments, but more research is needed to improve hair regeneration methods.
The study found that bioengineered hair follicles work when using cells from the same species but have issues when combining human and mouse cells.
Grafted rodent and human cells can regenerate hair follicles, but efficiency decreases with age.
Versican, a protein, is less present in thinning hair follicles and this decrease might contribute to common hair loss in men.
Cells from a skin condition can create new hair follicles and similar growths in mice, and a specific treatment can reduce these effects.